CNBC Television• Dec 18, 2025• 1:20

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Executive Summary

Eli Lilly's trial data indicates its oral obesity pill is effective as a maintenance therapy for patients who have already lost weight using injectable drugs like Wegovy and Zepbound.
Patients switching from injectables to Lilly's oral pill maintained most of their weight loss after a year, with minimal regain, validating the maintenance treatment strategy.
The oral pill is positioned to capture a new segment of the weight loss market, potentially boosting uptake by offering a more convenient long-term option than weekly injections.
While initial pricing for starting doses is hinted at $150/month through a future direct-to-consumer platform, final pricing and regulatory approval for the oral drugs from both Lilly and Novo Nordisk remain uncertain.

7 quotes

Concerns Raised

The oral obesity pills from Eli Lilly and Novo Nordisk have not yet received regulatory approval.
Final pricing, especially for higher doses, remains unknown and is a key variable for market uptake.
The long-term viability and launch details of the direct-to-consumer platform are not yet confirmed.

Opportunities Identified

Eli Lilly can establish a new market segment for oral maintenance therapy, capturing patients for long-term treatment.
The convenience of a daily pill over a weekly injection could significantly improve patient adherence and expand the total addressable market.
The potential for a lower price point compared to injectables could improve accessibility and payer coverage.

Key Themes

Evolution of Obesity Treatment

The market is shifting from initial, high-efficacy injectable treatments to a new phase of long-term oral maintenance therapies. This creates a new paradigm where patients transition between different drug formats for sustained weight management.

This signifies a maturing market for GLP-1 drugs, creating a new, long-term revenue stream for pharmaceutical companies and offering patients more convenient, less invasive options for chronic care.

Eli Lilly's Competitive Strategy

Eli Lilly is strategically positioning its oral drug not just as a competitor to other pills, but as a complementary follow-on therapy to its own and competitors' injectable products. The clinical trial was specifically designed to prove this maintenance use case.

This strategy could allow Lilly to capture patients from its main competitor, Novo Nordisk, by offering an effective and convenient 'off-ramp' from injections, thereby expanding its total market share.

Drug Pricing and Accessibility

The final cost of oral obesity pills is a major unknown, but early indications suggest a potential for lower monthly prices than injectables, at least for starting doses. The emergence of direct-to-consumer platforms like the mentioned 'Trump Rx' could also alter the distribution and access landscape.

Pricing will be a critical factor for market adoption and payer coverage. A lower-cost oral maintenance option could significantly broaden patient access and adherence over the long term.

The Importance of Clinical Endpoints

The trial's success was defined by the maintenance of weight loss, not just initial weight loss. Patients who switched to the pill regained only a small fraction of the weight they had lost, demonstrating the drug's efficacy for long-term management.

This data provides strong clinical evidence for a maintenance-focused treatment approach, which is crucial for gaining regulatory approval and convincing clinicians and payers of the drug's long-term value.

Get started free

Topics

Eli Lilly Novo Nordisk Obesity Drugs Weight Loss GLP-1 Maintenance Therapy Oral Medication Injectable Drugs Wegovy Zepbound Clinical Trials Drug Pricing Regulatory Approval Direct-to-Consumer Pharmaceuticals

Processed Apr 20, 2026 yt-dlp + mlx-whisper + Gemini